

Index

A

- AAV. *See* Adeno-associated virus (AAV)
- ABCA4* gene, 408–409
- ABCA4*^{-/-} mouse eyecups, 763–764
- Abe, T., 305
- ABI/SOLiD platform, 755
- Ablonczy, Z., 75
- Achromatopsia (ACHM), 183. *See also* Cyclic nucleotide-gated (CNG) channels
- Adamowicz, M., 573
- Adaptive optics (AO) imaging
 - analysis and interpretation, 451–452
 - bull's eye maculopathy, 454–455
 - clinical examination, 452
 - dominant drusen, 452–454
 - retinal atrophy and visual loss, 454–456
- Adeno-associated virus (AAV), 180
 - rescued retinal function, 202–203
 - retinal structure integrity, 201–202
 - RHO301* gene expression, 201
 - usher syndrome type 1B, 239
 - XIAP protein, 211–212
- Adenosine 5'-triphosphate (ATP), 813
 - degradation, 814
 - and purinergic receptors, 813
 - storage and release of, 814
- A2-dihydropyridine-phosphatidylethanolamine (A2-DHP-PE), 764–765
- ADRP. *See* Autosomal dominant retinitis pigmentosa (ADRP)
- Advanced glycation end product (AGE), 765
- A2E, 725, 763
- AFF. *See* Autofluorescent foci (AFF)
- Age-related macular degeneration (AMD), 62, 64, 65, 67–68
 - angiogenic response, 273
 - ARMS2*, 369–370
 - chronic age-related disease, 727
 - diagnostic tools, 274
 - histopathological analysis, 726
 - HTRA1*, 370
 - neovascular ocular diseases, 246
 - retina, 272
 - retina autophagy (*see* Autophagy)
 - retinal neovascular disorders, 255
 - risk factors, 726
 - therapeutic approaches, 270
 - VEGF levels, 272
- Aguayo, 161
- Aguirre, G.D., 321, 353, 611
- Ahern, K., 553
- AIF. *See* Apoptosis-inducing factor (AIF)
- Airaksinen, S., 668
- Akopian, A., 739
- Albarracin, R.S., 121
- Ali, R.R., 17, 177
- Allikmets, R., 368
- All-*trans*-retinal dimer phosphatidylethanolamine, 763–764
- Al-Ubaidi, M.R., 835
- Ambati, J., 3
- AMD. *See* Age-related macular degeneration (AMD)
- AMP-activated protein kinase (AMPK)
 - cellular process, role in, 746
 - and RPE cell function
 - allosterical activation, 746
 - cell barrier function, 747–748
 - cell inflammatory response, 748–749
 - cell survival, 749
 - phagocytosis, 748
 - via Thr¹⁷²Pphosphorylation, 746–747

- AMP-activated protein kinase
(AMPK) (*cont.*)
Ser/Thr kinase, 746
subunit, 746
- Amyloid- β role
AMD, 67–68
cytotoxic, neural retina, 69–70
drusen component, 68
proinflammatory retina, 70–71
RPE cell structure and function, 68–69
- Amyloid precursor protein (APP), 68
- Anand-Apte, B., 261, 293
- Anderson, R.E., 129
- Angiogenesis, 681
- Animal model
rd 10 mice, RPE sheet analysis (*see* Rd10 mice, retinal degeneration model)
ROM-1 overexpression
electron microscopy, 635
electroretinography, 634–635
gel electrophoresis, 634
transgenic mice, 634
western blot analysis, 634
- Annear, M.J., 177
- Annexin 2 (anxA2), 720
- Apolipoprotein, 726
- Apoptosis, 207
- Apoptosis-inducing factor (AIF), 210
- Apoptotic cell death, 554
- Aranesp/AMG114, 138, 139
- Arinobu, D., 823
- Aron, L., 415
- Arrestin 1 (Arr1)
dark-or light-adapted retinas, 793–795
protein–protein interaction, 793
- Arylalkylamine N-acetyltransferase
(AANAT), 824
- Aryl hydrocarbon receptor (AhR)
AMD pathogenesis, 55–56
cellular oxidative stress response, 54
cigarette smoke, 52
genetic linkage and genome-wide association study, 51–52
molecular and biological mechanism, 51
proteosomal degradation, 54–55
RPE cellular response, oxidant injury, 52–53
- Association for Research in Vision and Ophthalmology, 642
- Autofluorescent foci (AFF), 464
- Autoimmune biomarkers
“after-the-fact” phenomenon, 14
AMD pathogenesis, 12–13
immunomics, 15
inflammation and immune system, 12
proinflammatory factors, 14
protein modification, 11
role of autoimmunity, 13–14
- Autophagy, 208
AMD, 87–88
molecular events, 84–85
neural retina, 85–86
RPE, 86–87
signaling mechanisms, 85
- Autophagy-related proteins (Atg), 84
- Autosomal dominant cone and cone-rod dystrophy
characterisation, 337
genetic analyses, 338
hereditary retinal dystrophies, 337
mutation spectrum, 338–340
patients and clinical examinations, 338
- Autosomal dominant retinitis pigmentosa (ADRP), 191, 215, 500–502, 573
AAV gene delivery
rescued retinal function, 202–203
retinal structure integrity, 201–202
RHO301 gene expression, 201
animal models, 200
electroretinography, 200–201
outer nuclear layer, 201
RHO301 gene cloning, 200
- Axonal guidance. *See* Homeobox genes
- Ayyagari, R., 225
- B**
- Bachor, T.P., 101
- Bagheri, N., 479
- Bai, L., 183
- Bainbridge, J.W., 177
- Bai, Y., 299
- Balaggan, K.S., 271
- Balb-c male mice, 102
- Bandyopadhyay, M., 23
- Bardet–Biedl syndrome (BBS), 533
- Barker, S.E., 177, 180
- Barrier modulation
characteristics, 157–158
Claudin-5, 156
IMPDH1 gene, 156, 157
potential benefits, 156, 157
RPE, 157
- Barstable, 758
- Bartoe, J.T., 177
- Basavarajappa, D.K., 829
- Basic helix–loop–helix (bHLH), 686
- Bassoon KO mice, 740, 741

- β -carotene monooxygenase 1 (BCMO1), 168
 BCM. *See* Blue cone monochromacy (BCM)
 Beaulieu, C., 371
 Becerra, S.P., 799
 Bech-Hansen, N.T., 371
 Becirovic, E., 183
 Beck, S.C., 183
 Bell, B.A., 459, 479
 Beltran, W.A., 353
 Bennett, J., 129
 Bernd, A., 471
 Best corrected visual acuity (BCVA), 472
 Best disease, 604
 BEST1 missense mutations
 anion channel malfunction, 612
 BVMD, 611, 616
 canine bestrophin-1 topology, 613–614
 cellular homeostasis, 616
 comparative protein modeling, 613–615
 membrane protein, 616
 protein structure, 613
 topological model, 612–613
 Bestrophin-1. *See also* BEST1 missense mutations
 anion conductance loss, 604
 cytoplasmic function, 607–609
 function, 604
 localization, 604–606
 retinal degeneration, 603
 vitelliforme macular dystrophy, 604
 Best vitelliform macular dystrophy (BVMD), 604, 611, 616
 Betacellulin (BTC)
 angiogenesis, 295
 biological functions, 294
 future aspects, 296
 role, retina, 295
 structure and expression, 294
 Bian, Q., 43
 Biel, M., 183
 Birch, D.G., 313, 497
 Bis-retinoid precursors, 75
 Bisretinoids, RPE lipofuscin
 A2-DHP-PE, 764–765
 all-*trans*-retinal dimer vs.all-*trans*-retinal dimer PE, 763–764
 biosynthetic pathways, 761–762
 photooxidation, 765
 Blacque, O.E., 433
 Blanks, J., 269
 Blast-like alignment tool (BLAT), 522, 523
 Blood-retinal barrier (BRB)
 Claudin-5 siRNA, 156–157
 iBRB modulation, 158–159
 IMPDH1 gene, 156, 157
 potential benefits, 158
 RPE, 157
 tight junctions, 155–156
 Blue cone monochromacy (BCM), 599
 Blue light damage
 apoptosis, 619
 cryosection, 623
 DNA microarray, 620
 histological investigation, 629
 MacGreen mice, 620
 microglia accumulation, 622–623
 quantitative real-time PCR, 620–621
 retinal cross sections and whole mounts, 620
 retinal degeneration, 619
 RNA isolation and reverse transcription, 620
 transcriptomic changes
 DNA microarray analysis, 623, 624
 expression, 625–628
 microarrays algorithm, 624
 qPCR validation, 629
 Blue native-PAGE
 analysis of, 773
 detergents, 770
 protein complex separation, 774
 Boatright, J.H., 641
 Bonilha, V.L., 479
 Bothnia-type retinal dystrophy
 11-*cis*-retinal
 illumination, 590
 photoisomerization, 592–593
 CRALBP WT and R234W
 expression, purification,
 crystallization, 590
 ligand-binding cavity, 592
 structure determination, 590–592
 crystallographic statistics, 593
 RLBP1 gene, 589
 Boulton, M.E., 83, 726
 Bovine ocular tissues
 isolation of, 836
 PSG2 antibody, 838–839
 SDS-PAGE, 836–837
 S-IRPEM vs. IS-IRPEM, 838, 839
 Western blot analysis, 837–838
 Bowles, K.E., 505
 Bowne, S.J., 313
 Braunger, B.M., 679
 Bredberg, D.L., 590
 Bright-field macroscopic imaging, 480
 Brij 96, 770
Brn-3 genes, 686–687
 Brombas, A., 807
 Bruban, J., 67

- Bruch's membrane (BM), 12, 725, 765
 Brush, R.S., 553
 BTC. *See* Betacellulin (BTC)
 Bulls' eye maculopathy, 454, 455
 Büning, H., 183
 Butler, M.C., 145
 BVMD. *See* Best vitelliform macular dystrophy (BVMD)
- C**
 Caberoy, N.B., 693
Cacnalf gene, 739
Caenorhabditis elegans, BBS proteins
 cellular functions, 534
 IFT transport, 534–535
 nephronophthisis, 534
 photoreceptor degeneration, 536–537
 phototransduction, 536
 pleiotropic disorder, 533
 primary cilium, 534
 RPE cells, 535
 Cai, J., 83
 Cai, X., 245
 Calof, A.L., 671
 Calpain and photoreceptor apoptosis
 age-related macular degeneration, 547
 barrier modulation, 551
 blood retina barrier, 549
 calpain activation, 548–549
 calpain inhibitors, 549
 caspase 8, 548
 transgenic mouse models, 549
 Campbell, M., 155, 547, 567
 Canine-specific TaqMan assay, 361
 Carboxy-ethyl-pyrrole (CEP), 13
 Carroll, J., 451
 Caspase 8, 548
 Caspase-dependent apoptosis, 5
 Castañeda, M.M., 101
 Cav1.4 α 1 subunit
 Cacnalf gene, 739
 knockout mice, 740
 loss of, 742
 Cdc42, 583
 Cell death
 autophagosome, 208
 characterisation, 207
 future aspects, 212
 inherited retinal dystrophies, 209–210
 macroautophagy, 208
 mammalian autophagy, 208
 pathway blockage, 211–212
 retinal damage models, 210–211
 TOR kinase, 208
 Cellular homeostasis, 83
 Cellular retinaldehyde-binding protein (CRALBP)
 11-*cis*-retinal
 illumination, 590
 photoisomerization, 592–593
 expression, purification, crystallization, 590
 ligand-binding cavity, 592
 structure determination, 590–592
 Ceramide kinase like (CERKL) gene, 555
 Ceramide signaling
 apoptotic cell death, 554
 bioactive sphingolipids, 553
 Cer production, 554
 photoreceptor apoptosis, 554–556
 RPE cell death, 556
 Cerebral neurodegenerative disease, 65
 Cer-induced RPE apoptosis, 556
 CFF. *See* Critical flicker frequency
 Chakraborty, D., 633, 657
 Chalmers, K.J., 367
 Chang, B., 130
 Chavali, V.R.M., 225
 Cheetham, M.E., 527, 595
 Chemical cross-linking
 amino-specific cross-linker BS³, 770
 with infrared fluorescence detection, 772, 774
 Nrl-/-retina membrane, 770
 protein complex evaluation, 772
 Chemical mutagenesis, 400
 Chemotactic cytokines, 39
 Chen, H., 553
 Chiang, W.-C., 559
 Choroidal neovascularization (CNV), 4, 254
 CCR3
 animals and subretinal Matrigel injection, 280
 antagonist SB328437 effects, 281–283
 blood vessels and measurement, 280
 Matrigel model, 280–281
 role of, 279
 constitutive vs. regulated expression, 270–271
 endostatin effectiveness, 273–274
 hypoxia-regulated expression, 272–273
 RPE-specific promoters, 271–272
 Choroidal vascular development
 animal experiments, 300
 choroidal vessels, 303
 quantification, 300–301
 retinal integrity, 301
 RPE-produced VEGF, 301

- Choroideremia (CHM)
 affected family members, 383
 clinical characteristics, 383
 confocal microscopy, 382–383
E. coli particles, 383
 FACS analysis, 382–383
 gene replacement, 386
 lysosome-mediated degradation, 386
 patient population, 382
 proteolytic degradation, 385
 trafficking defects, 386
- Chow, A.Y., 115
- Chrenek, M.A., 641
- Chromatin immunoprecipitation (ChIP), 754
- Chromatin signatures, 756–757
- Chromosome 10q26 susceptibility
ARMS2, 369–370
 genetic association, 368–369
- Ciavatta, V.T., 115
- Ciliary neurotrophic factor (CNTF)
 adaptive optics scanning laser
 ophthalmoscopy, 98
 cone degeneration, 94
 COS regeneration, 96–97
 light-sensing function, 97
 loss of cones, 95
 loss of COS progress, 94–95
 PNA-negative areas, 96
 retinal degeneration, 94
 S334ter rats, 94
- Ciliopathy, 318
- Circadian rhythms, 718
- cmr2* mutant, 613, 614
- CNGA3
 achromatopsia, 183
 electrophysiological analysis, 184
 ERG measurements, 186
 ganglion cells activation, 187
 immunohistochemistry, 185
 mouse expression, 185
 photoreceptor function, 185–186
 rAAV vectors and injection, 184
 retinal cone-mediated signaling,
 187–188
 water habituation, 185
- CNV. *See* Choroidal neovascularization
 (CNV)
- Coat's disease, 680
- Cochran's *t*-test, 643
- Colley, N.J., 407
- Collin, R.W.J., 345
- Cone dystrophy. *See* *OPN1LW* and *OPN1MW*
 cone opsin gene
- Cone opsin promoter (COP-T), 659
- Cone photoreceptors
 ROM-1 protein
 electron microscopy, 635
 electroretinography, 634–635
 gel electrophoresis and western blot
 analysis, 634
 ROM-1 overexpression, cone function
 and structure, 635–637
 ROM-1 protein expression, transgenic
 mice, 635, 636
 transgenic mice generation, 634
- Cone-rod dystrophy (CRD), 321, 497
- Congenital stationary night blindness
 clinical phenotype, 377
 clinical variability, 375–376
 ERG features, 377
 genetic analysis, 372
 CACNA1F mutations, 373
 GRM6 mutations, 374
 NYX mutations, 374
 TRMP1 mutations, 374
 X-linked CSNB, 375
 negative bright flash ERG, 377
 nystagmus, 377
 statistical Analysis, 372
 strabismus, 377
 subjects, 372
- Conley, S.M., 633, 657
- Connor, T.B. Jr., 451
- Coomassie blue staining, 773
- Corbo, J.C., 757
- Cotter, T.G., 549
- C1q tumor necrosis factor-5 (*CIQTNF5*/
CTRP5), 225, 226
- Craft, C.M., 253, 791
- CRALBP. *See* Cellular retinaldehyde-binding
 protein (CRALBP)
- Cremers, F.P.M., 345
- Critical flicker frequency (CFF)
 ERG protocol, 506–507
 ISCEV standard tests, 506
 photopic, 508–510
 scotopic, 507–508
- Cronin, T., 129
- Crouch, R.K., 75
- CRX
 photoreceptor terminal
 determination, 757
 retinal development, *vsx2*, 675
- Cubilla, M.A., 101
- Cutler, A., 293
- Cyclic guanosine monophosphate (cGMP)
 channel
 light adaptation, 781

- Cyclic guanosine monophosphate (cGMP) channel (*cont.*)
 N-terminal and C-terminal region, 778
 phototransduction, 781
 subunits, 777
- Cyclic nucleotide-gated (CNG) channels
 cell culture studies and vectors, 778
 cone
 blue native-PAGE, 770
 chemical cross-linking, 770, 772
 infrared fluorescence Western detection, 770
 stoichiometry of, 773–774
 subunits, 769
 PHLPP1 and PHLPP2
 modulatory properties, lack of, 780–781
 RA domain assessment, 779–780
 RA/RBD domain-containing proteins, 778
 rods, 769
 sequence alignment and domain assessment, 778
 statistical methods, 778
 visual and olfactory transduction, 777–778
- Cytosolic protein cone arrestin (CAR), 659
- D**
- Dahrouj, M., 23
 Daiger, S.P., 313
 Dalal, N., 641
 Dark-adapted rod electroretinogram, 497
 Dark-rearing *rd10* mouse
 candidate retinal genes, 132
 C57Bl/6J, 130
 electroretinogram, 130–131
 immunohistochemical analysis, 132
 immunolabeling, 131
 LR-*rd10* mice, 133, 134
 phosphodiesterase 6b mutation, 129
 P23H-3 transgenic mouse, 133
 PNM3, 131–132
 QrtPCR analysis, 131
 retinal gene expression, 135
 rod function, 134
 RTPCR, 129
- Dean, M., 368
 De Laurenzi, V., 732
 Dendritic cells (DCs), 12
 den Hollander, A.I., 345
 Desiderio, D.M., 11
 Devery, S., 595
 Dexamethasone (DEX), 101, 105
 Dhubhghaill, S.N., 155
- Diabetes, betacellulin, 295
 Diabetic retinopathy, 293
 neovascular ocular diseases, 246
 pericyte injury, 285
 retinal neovascular disorders, 254
- Dickkopf (DKK)-1, inhibitor, 681
 Dinet, V., 67
 Ding, X.-Q., 633, 769
Dlx genes, 687–688
 DNA microarray, 620
 Dodecylmaltoside (DDM), 770
 Donovan, M., 549
 Dorey, C.K., 269
 Double-stranded RNA (dsRNA), 4
Drosophila photoreceptor degeneration, 556
 Dryja, T.P., 411
 Dunn, W.A. Jr., 83
 Dwyer, M., 51
- E**
- Ebenezer, E.D., 595
 Ebert, S., 619
 Ectonucleoside triphosphate diphosphohydrolases (E-NTPDases), 814
 Eisenstat, D.D., 685
 Elastokines, 64
 Electroretinogram (ERG), 506–510, 823
Arr1^{-/-} mice, 793
 autosomal dominant retinitis pigmentosa, 200–201
 photopic CFF, 508–510
 protocol, 506–507
 retinal photoresponses, *HCN1*^{-/-} mice, 809
 ROM-1 overexpression, 634–635
 scotopic CFF, 507–508
 small interfering RNA, 217
 standard ISCEV flicker test, 506, 510
 translational vision research models program, 392
- Endogenously expressed bestrophin-1, 605
 Endoplasmic reticulum, 289, 290, 607, 608
 Endoplasmic reticulum-associated degradation (ERAD)
 cytosolic events, 561–562
 dislocation, 560–561
 glucosidase activation, 559
 misfolded proteins recognition, 560
 P23H rhodopsin, 562–563
 protein-folding cycle, 560
 quality control, 559
- Endostatin, 273–274
 Endotoxin-induced autoimmune uveitis (EAU), 20

- Enhanced S cone syndrome (ESCS), 823
 ENU mutagenesis. *See* *N*-ethyl-*N*-nitrosourea (ENU) mutagenesis
 Epidermal growth factor (EGF), 294
 Epidermal growth factor receptor (EGFR), 830
 Epitope-tagged PEDF-R expression, 800
 ERG. *See* Electroretinogram (ERG)
 Erythropoietin (Epo), 138
 glycosylation analogs, 141
 overexpression, 140
 retinal protection, 140
 External limiting membrane (ELM), 454
 Extracellular matrix (ECM), 370, 838
 Eye development, 399–400
- F**
 Factor XIIIa, Goldfish
 cDNA clone, 449
 cloning, 446
 gene expression change, 447–448
 induced neurite outgrowth, 448
 transglutaminase (TG), 445
fad mutant, 441
 Fahim, A.T., 313
 Fahl, E., 183
 Familial exudative vitreoretinopathy (FEVR), 680
 Familial (Mendelian) maculopathies, 62
 Fariss, R.N., 661
 Farkas, M.H., 519
 Farrar, G.J., 567
 Fat-liver dystrophy (*fld*) mouse, 655
 Faulkner, A.E, 115
 Fenretinide
 amine analog, 172
 BCMO1 inhibitor, 169–170
 BSG1 enzyme, 168
 cancer treatment, 167
 catalytic activation, 170, 172
 constructs, 168
 HPLC analysis, retinoid and carotenoids, 168
 molecular docking, 169
 noncompetitive inhibition behavior, 170, 171
 protein expression and enzyme assay, 168
 RBP4, 167
 synthesis, 168–169
 tertiary structure modeling, 169
 Fibroblast growth factors (FGFs), 302
 Finnemann, S.C., 709, 731
 Fischer, M.D., 183, 491
 Flatmount technique, 642
 Fletcher, E.L., 813, 816
 Focal adhesion kinase (FAK), 719
 Fong, W.G., 207
 Fourier transforms (FFTs), 507
 Fritsche, L.G., 369
 Frizzled 4 (Fzd-4), 681
 Fujikawa, C., 663
 Fukada, 823
- G**
 Ganglion cell functions, 476
 Ganglion cell layer (GCL), 675, 687
 Gardner, C., 641
 Gardner, J.C., 595
 Geisert, E.E., 649
 Gel electrophoresis, 634
 Gene expression, retinal injury
 in adult rats, 649
 bioinformatic analyses, 651, 653–654
 in *fld* mice, 655
 network modulation, 651–653
 online databases, 651, 653–654
 patterns of, 650
 Gene therapy
 AAV-mediated gene therapy, 239
 AMD, 270
 HRE, 272
 lentivirus-mediated gene therapy, 237–239
 RDS/peripherin disease., 216
 Genini, S., 353
 Genome-wide occupancy analysis
 ChIP-chip and ChIP-Seq
 ChIPed DNA, 755
 NGS platforms, 755–756
 in vivo protein-DNA interactions, 754
 transcription regulatory network
 histone modifications, 756–757
 transcription factor, 756
 Gentleman, S., 167
 Gerling, I.C., 11
 Glaucoma, 655, 816
 Glucocorticoid-dependent mechanisms
 balb-c male mice, 102
 caspase-3 activation, 103–104
 DEX, 101, 105
 GR α immunoreactivity, 104
 light-exposed retinas, 102–103
 mifepristone, 101, 105
 mineralocorticoid receptor, 105
 OS damage, 105
 rhodopsin, 103
 Gobbo, O.L., 155
 Godara, P., 451
 Gollisch, T., 183
 González-Duarte, R., 329

- Gorbatyuk, M.S., 191, 199, 569
 Gorbatyuk, O.S., 191
 G-protein-coupled receptor (GPCR), 18, 793
 G protein-coupled receptor kinase (GRK)
 in changing light conditions, regulation of,
 823–824
 expression of, 822
 function of, 822–823
 photoreceptor, distribution in, 822
 retinopathy, role in, 821
 Grant, G.R., 519
 Grant, M.B., 83
 Graphpad Prism software, 778
 Greferath, U., 813
 Gregory-Evans, C.Y., 399
 Grey, A.C., 75
 Griciuc, A., 415
 Grimm, C., 491, 581
 Grossman, G.H., 293, 701, 783
 Grossniklaus, H., 641
 Growth and differentiation factor 11 (GDF11)
 olfactory epithelium (OE), 672
 retinal ganglion cells, 672
 retinal neurogenesis, negative regulator
 of, 672
 signaling molecule, 672
 transcription factor, role in, 673
 Vsx2^{ort/ort} mouse retina
 animal model, 673
 epithelial thickness and cell
 lamination, 674
 gene expression, 675
 histology and in situ hybridization, 673
 rescued expression, 674
 retinal development, restoration of, 675
 Growth factor receptor-bound protein 14
 (Grb14), 778
 Gubin, A., 167
 Gu, J., 15
 Guo, D.C., 315
 Gupta, V.K., 777, 829
 Gutierrez, D.B., 75
 Guziewicz, K.E., 611
- H**
 Hagstrom, S.A., 701, 783
 Hamilton, J.A., 671
 Hamilton, R.A., 835
 Hammerhead ribozyme (hhRz), 147
 Hanrahan, F., 155
 Hao, H., 753
 Hardcastle, A.J., 527, 595
 Hauswirth, W.W., 191, 199, 215
- HCN1 channels
 HCN1^{-/-} mice, retina
 flicker fusion frequency, 810, 811
 single-flash ERG response, 808–809
 knockout mice, 807
 photoreceptor
 mechanism in, 808
 shaping and shortening, 807
 HDAC I/II inhibitors, 109
 HDAC inhibition, *Rd1* mouse
 C3H wild-type mice, 108
 HDAC assay, 108
 histone modifications, 107
 molecular cell death pathways, 112
 PARP activity, 109–110
 photoreceptor cell death, 108
 rd1 photoreceptors, 111
 rd1 retina, 109
 rhodopsin, 111
 TUNEL and immunostaining, 109
 in vitro retinal explant cultures, 108
 Heat shock proteins (HSPs), 567
 heat shock factor-1, 663
 role, 663
 Hedstrom, L., 539
 Heintzman, N.D., 757
 Héon, E., 533
 Hereditary retinal degeneration, 93
 He, X., 589
 Heynen, S.R., 581
 Hicks, W., 391
 Hindges, R., 671
 Holder, G.E., 595
 Hollyfield, J.G., 459, 479
 Homeobox genes
 Brn-3 genes, 686–687
 Dlx genes, 687–688
 islet genes, 689
 Vax genes, 688
 Homeodomain (HD), 686
 Homozygosity mapping
 autosomal recessive disease, 346
 consanguineous vs. nonconsanguineous
 families
 ABCA4 mutation, 348
 arCRD cohorts, 349
 arRP genes, 348
 retinal dystrophy genes, 349
 schematic representation, 347
 future aspects, 350
 population composition, 349
 single nucleotide polymorphisms, 346
 strengths and limitations, 350
 Hood, D.C., 497

- Hoppe, G., 701
 Horner, T.J., 823
 Huang, D., 93, 279
 Huang, S.-P., 791
 Huber, G., 183, 491
 Human bestrophinopathy, 615
 Human postmortem eyes
 AMD retina, 483–485
 bright-field macroscopic imaging, 480
 macular hole, 482, 483
 normal retina, 481–482
 OCT, 481, 487
 RPE detachment, 482–484
 RP retina, 484–486
 SLO, 480–481
 tissue preparation, 480
 in vivo imaging, 485–487
 Human retinal gene (HRG), 529
 Human retinal pericytes
 activating transcription factor 4, 287–289
 C/EBP homologous protein, 287–289
 cell culture, 286
 ER stress inhibition, 289, 290
 glucose fluctuation, 285
 glucose regulated protein (GRP78), 287
 macrophage chemoattractant protein 1,
 285, 287
 materials, 286
 statistical analysis, 287
 western blot analysis, 286
 Humphries, M.M., 155, 547, 567
 Humphries, P., 155, 491, 547, 567
 Hyde, D.R., 427
 Hydroquinone (HQ), 27
 4-Hydroxy(phenyl) retinamide (4-HPR). *See*
 Fenretinide
 Hyperoxia, 33–34
 Hypoxia-regulated expression, 272–273
 Hypoxia-response elements (HREs), 272
- I**
 Iannaccone, A., 11
 IFT. *See* Intraflagellar transport (IFT)
 Illumina platform, 755
 Immunomics, 15
 Induced pluripotent stem (iPS) cells, 523
 Infrared fluorescence Western detection
 cone CNG channel
 advantages of, 774
 blue native-PAGE, analysis by, 773
 chemical cross-linking, 772–773
 CNGA3 and CNGB3, simultaneous
 detection of, 771
 mouse retinal membrane protein, 770
 Nrl^{-/-} retina, 770
 Ingenuity pathway analysis (IPA), 360
 Inner blood retina barrier (iBRB), 550
 Inner plexiform layer (IPL), 704
 Inosine 5 ϵ -monophosphate dehydrogenase
 (IMPDH1), 539
 Inositol 1,4,5-triphosphate (InsP₃), 720
 Institutional Animal Care and Use Committee
 of the Cleveland Clinic, 702
 Insulin receptor (IR) signaling
 and PTP1B
 in diabetes, 831
 interaction between, 830–831
 in retina, 830
 Intracellular trafficking genes
 intraflagellar transport, 438–439
 membrane transport, 440
 microtubule-dependent molecular motor, 439
 Intraflagellar transport (IFT), 438–439, 529
 IRDye-680 fluorescence dye, 770
 Ishikawa, Y., 305
 Islet genes, 689
- J**
 Jiang, Y., 641
 Jin, H., 535
 Jobling, A.I., 813
- K**
 Kanan, Y., 835
 Kanda, A., 369
 Kang, M.J., 420
 Kanuga, N., 595
 Kato, S., 161, 445, 663
 Kaul, C., 459
 Kauper, K., 93
 Kawamura, S., 823
 Keaney, J., 567
 Kenna, P.F., 155, 547, 567
 Kennedy, B.N., 433
 Kiang, A.-S., 155, 547, 567
 Kim, M.K., 115
 Kitiratschky, V., 337
 Kleinman, M.E., 3
 Knockdown technology, 401
 Knockout mouse models, 516
 Koch, S., 183
 Kohl, S., 337
 Kolniak, T.A., 145
 Komori, N., 769
 Koriyama, Y., 161

- Kortvely, E., 61, 369
 Kraft, T.W., 503, 505
 Krishnamoorthy, V., 183
 Krishnamurthy, P., 11
 Krizaj, D., 739
 Kroeger, H., 559
 Kumasaka, N., 305
 Kunchithapautham, K., 23
 Kurtenbach, A., 471
 Kuznetsova, T., 321
- L**
- Laird, J., 167
 Lakkaraju, A., 723
 Langmann, T., 619
 Laser microdissection (LMD), 703–704
 Late endosome–lysosome
 cholesterol trafficking, 723
 function and dysfunction, 724–725
 health and disease, 727–728
 protein–lipid sorting, 723
 in RPE, 725–726
 signaling, 723
 Laties, A.M., 93
 LaVail, M.M., 93, 191, 215, 553
 Law, A.-L., 717, 718
 LDL receptor-related protein (Lrp), 680
 Leber congenital amaurosis (LCA), 177, 540
 Lechtreck, K.F., 535
 Lenchik, N.I., 11
 Lentivirus-mediated gene therapy, 237–239
 Lewin, A.S., 191, 199, 215
 Le, Y.Z., 299
 Li, F., 129
 Light-damaged zebrafish retina
 induction of Müller glial proliferation, 429
 regeneration, 428–429
 Light-induced retinal degeneration, 34, 102–103
 apoptotic cell death, 122
 cone opsin gene regulation, 125
 cone photoreceptor function, 122
 emerging therapeutic modality, 126
 gap and *fgf* genes, 122
 histopathological changes, 126
 opn1mw gene expression, 127
 OS, photic injury, 123–125
 photoreceptor cell death, 123
 postcon retinas, 127
 retinal dystrophies, 121
 retinal function, photic injury, 125–126
 Lin, J.H., 191, 559
 Lipid storage disease, 555
 Lipofuscin (LF), 24, 75–76, 80, 85, 88
 accumulation, 86
 late endo-lysosome, RPE, 725
 in RPE
 amino acid analysis, 761–762
 bisretinoids (*see* Bisretinoids, RPE lipofuscin)
 Littink, K.W., 345
 Liu, J., 536
 Li, W., 693
 Li, Y., 93, 279
 Lobsiger, J., 589
 Local vs. systemic mononuclear phagocytes
 CCR2 and CX3CR1 signalling, 19–20
 cellular innate immune system, 21
 chemokine mouse model, 20
 chemokine receptor CX3CR1, 19
 CNV, 17
 geographic atrophy, 17
 microenvironment signals, 18
 myeloid cells, 19
 reticular drusen, 21
 systemic and local innate immune cells, 18
 Locke, K.G., 497
 Lodha, N., 371
 Lohr, H.R., 210
 Lopes, V.S., 235
 Loucks, C.M., 371
 Luhmann, U.F.O., 17
 Luibl, V., 68, 69
 Luo, L., 93, 279
 Lutein/zeaxanthin supplementation
 ARPE-19 cells, 45
 C57BL mice, 47–48
 cell culture and treatment, 45
 dietary supplementation, 48
 experiments with animals, 44–45
 immunoglobulin accumulation, 44
 light-induced photoreceptor death, 44
 materials, 44
 oxidative stress, 43
 primary macrophage culture, 46–47
 pro-inflammatory cytokines, 49
 RPE, 45–46
 visual loss protection, 43
 Lysosomes, 85
 Lyubarsky, A., 129, 131
- M**
- MacDonald, I.M., 381
 Macroautophagy, 83, 208
 Macrophage chemoattractant protein 1 (MCP-1), 285
 Macula lutea, 61

- Macular drusen, 452
 Macular edema, 61
 Macular hole, 482, 483
 Maculopathy
 extracellular matrix role, 65
 macula lutea, 61
 pathomechanisms, 64
 risk factors, 64–65
 shared protein networks, 62–63
 Madin–Darby canine kidney (MDCK) cells
 cell culture, 354, 359
 cellular viability assessment, 359
 Maher, A.R., 595
 Malek, G., 51
 Mandal, M.N.A., 553
 Mao, H., 199
 Marfany, G., 329
 Mascarelli, F., 67
 Matrix-assisted laser desorption/ionization (MALDI), 76
 Matsukawa, T., 161
 Matsumoto, H., 769
 Matthes, M.T., 215, 553
 Matveev, A., 769
 Ma, W., 37
 Mawatari, K., 663
 MBT. *See* Mushroom bodies tiny (MBT)
 McDonnell, D., 51
 McGinnis, J.F., 245
 McGrew, D.A., 539
 Medaka fish, 822
 Melanosomes, 238
 Melino, G., 732
 Membrane-associated protein cone transducin (GNAT2), 659
 Mer tyrosine kinase (MerTK), 694
 characterization of, 696–697
 ligand study, phagocytosis RPE, 694
 POS engagement, 719–720
 retinal degeneration, 693
 Michaelides, M., 595
 Michalakakis, S., 183
 Microglia
 cellular interaction, 40
 inflammatory mediators and neurotrophic agents, 37
 legal blindness, 37
 maladaptive inflammatory response, 38
 P2X7 receptor, retina, 817
 retinohoroidal interface, 38–39
 RPE interaction, 39–40
 Micro-ophthalmia, 671
 Microphotodiode arrays (MPA), 115–120
 Mifepristone (MFP), 103, 105
 Mikkelsen, T.S., 757
 Milenkovic, V.M., 603, 611, 616
 Milewicz, D.M., 315
 Milk fat globule EGF-factor (MFG-E8), 718–719
 Mitter, S.K., 83
 Mitton, K.P., 758
 Mok, C.A., 533
 Molday, L.L., 795
 Molecule-specific imaging and quantitation
 A2E generation, 80
 A2E oxidation sites, 78–79
 bis-retinoid precursors, 75
 LC-MS/MS-based technique, 80
 lipofuscin accumulation, 75, 80
 MALDI imaging, 76
 murine RPE, 77
 quantitation A2E, 77–78
 RPE tissue preparation, 76
 Moore, A.T., 595
 Moore, K.L., 835
 Morphometrics analysis software, 646
 Mowat, F.M., 177
 Mühlfriedel, R., 183
 Müller, C., 603
 Müller cells, P2X7 receptor, 816–817
 Müller, F., 807
 Müller glia, 429, 430
 Murine macrophages, 46–47
 Mushroom bodies tiny (MBT), 582–583
 Mutation in gene encoding, zebrafish
 intracellular trafficking genes (*see* Intracellular trafficking genes)
 phototransduction protein, 435, 438
 structural factor, 440
 structural protein, 440
- N**
 Naash, M.I., 633, 657
 Nagai, N., 305
 Nagashima, M., 663
 Naggert, J.K., 391
 Nakashima, H., 445
 Nandrot, E.F., 717, 718
 Nanoceria, 250
 Nash, Z., 633
 Natoli, R., 31
 Neeli, I., 11
 Nelson, C.M., 427
 Neovascular ocular diseases
 age-related macular degeneration, 246
 animal models

- Neovascular ocular diseases (*cont.*)
- Akimba (*Ins2 Akita VEGF+/-*) mouse, 248
 - Akita (*Ins2 Akita+/-*) mouse, 248
 - choroidal neovascularization, 247
 - vascular endothelial growth factor, 247
 - Vldlr* gene, 247
 - diabetic retinopathy, 246
 - oxygen induced retinopathy, 248
 - retinopathy of prematurity, 246
 - therapeutic treatment
 - angiogenic pathways, 248–249
 - nanomedicine, 249–250
 - regenerative medicine, 250–251
 - targeting pathology, 248–249
- Nepriylsin (NEP), 68
- N*-ethylmaleimide sensitive factor (NSF), 529
- ATPase activity, 793
 - domain structure, 792
 - homo-hexameric member, 792
 - photoreceptor
 - and Arrestin 1 (Arr1) (*see* Arrestin 1 (Arr1))
 - protein trafficking, 794–796
 - SNAP–SNARE binding, 792–793
- N*-ethyl-*N*-nitrosourea (ENU) mutagenesis, 391, 400
- Neural retina, 69–70, 85–86
- Neuronal progenitor cell proliferation, 429–430
- Neuroprotective dose response, RCS rats
- ERG testing, 119
 - light dosing, 116–117
 - microphotodiodes, 115
 - MPA device, 120
 - MPAs implantation, 116
 - photoreceptor numbers, 117
 - photoreceptor survival, 118
 - retinal function, 117–118
 - retinal function testing, 117
 - retinal preservation, 119
 - subretinal electrical stimulation, 116
 - xenon flashes, 119
- Neurotrophic growth factors, 681
- Neussert, R., 603
- Next generation sequencing (NGS), 350, 755
- bioinformatic analysis, 522–523
 - RNA-seq analyses, 523
- Nguyen, A.T.H., 155, 547
- Nickerson, J.M., 641
- Niemann–Pick C1 protein, 728
- Nishina, P.M., 391
- N*-methyl-*D*-aspartate (NMDA) injection, 681
- Noninvasive optical-biopsy, 479
- Norrin
- carboxyl-terminal cysteine-rich domain, 680
 - disease
 - congenital X-linked recessive disease, 680
 - missense mutations, 680
 - NDP* gene, 679
 - symptoms, 680
 - functions of, 682
 - in knock-in mouse model, 680
 - properties
 - angiogenic, 681
 - neuroprotective, 681–682
 - reproduction and development, role in, 682
- O**
- OCT. *See* Optical coherence tomography (OCT)
- Odyssey® Infrared Imaging System, 770
- Oguchi disease
- GRK1 retinopathy, 821, 822
 - in photoreceptor, NSF role, 796
- Ogun, O., 595
- Ogunshola, O.O., 581
- Oka, C., 370
- Oligomerization-incompetent RDS
- C150S-RDS protein, mislocalization of, 657–658
 - rods and cones
 - antibody and immunohistochemistry, 658
 - GNAT2 mislocalization, COP-T/WT, 660
 - M-opsin and COP-T mislocalization, COP-T/nrl^{-/-}, 659–660
 - transgenic mice, 658
 - transgenic mice, 657
- Onami, H., 305
- Oogai, K., 445
- OPNILW* and *OPNIMW* cone opsin gene
- cone dystrophy, 599
 - heterogeneous disorder, 595
 - immunoblotting and immunocytochemistry, 596–597
 - missense mutation, 599
 - molecular genetic analysis
 - array, 598
 - gene-specific primer, 596
 - P23H treatment, 599
 - RPGR* mutation, 597
 - W177R mutation, 598–599
 - ophthalmic assessment, 596
 - phenotype, 597

- polymorphism, 600
 - retinitis pigmentosa, 599
 - Opn1mw* gene expression, 127
 - Optical coherence tomography (OCT), 462–464, 466, 467, 479, 481
 - Optic nerve injury (ONI), 663
 - Optic nerve regeneration, gold fish
 - animal care, 446
 - factor XIIIa
 - cDNA clone, 449
 - cloning, 446
 - gene expression change, 447–448
 - induced neurite outgrowth, 448
 - transglutaminase (TG), 445
 - optic nerve transection, 449
 - retinal explant culture, 447
 - in situ hybridization, 446
 - wound healing, 445
 - Optic nerve repair
 - apoptosis, 165
 - IGF-I, 162
 - mammalian CNS injury, 165
 - neurite outgrowth-promoting factors, 162
 - nNOS, 163
 - optic nerve regeneration process
 - stages, 161
 - purpurin, 163–164
 - TG, 163
 - O’Riordan, C., 573
 - Osawa, S., 821
 - Ou, G., 534
 - Outer nuclear layer (ONL), 140, 142, 201
 - Outer plexiform layer (OPL), 701
 - Outer segment (OS) protein, 784
 - Oxidative stress, 747–748
 - Oxygen induced retinopathy, 248
- P**
- Papke, M., 337
 - Paquet-Durand, F., 107, 491
 - Parboosingh, J.S., 371
 - Pardue, M.T., 115
 - Pauer, G.J.T., 701, 783
 - pax6a* gene, 430
 - Peanut agglutinin (PNA), 94
 - PEDF. *See* Pigment epithelium-derived factor receptor (PEDF-R)
 - Penfold, P.L., 12
 - Peng, C., 774
 - Petersen-Jones, S.M., 177
 - Petr-Silva, H., 215
 - Phagocytosis, retinal pigment epithelium, 429
 - functional character of, 698
 - MerTK ligand study, 694
 - ORF phage, 694, 695
 - signaling, 693
 - Tulp1*^{-/-} mice, 694
 - Phosphatidylethanolamine (PE), 762
 - 3’-Phosphoadenosine 5’-phosphosulfate (PAPS), 835
 - Phosphodiesterase 6B (PDE6B), 641
 - Phosphoinositol (PI) signaling, 416
 - Phospholipase A₂ (PNPLA2), 800
 - Photic injury
 - OS, 123–125
 - retinal function, 125–126
 - Photopic critical flicker frequency, 508–510
 - Photoreceptor
 - apoptosis, 494, 554–556
 - cAMP-dependent protein kinase, 824
 - cell death, 123
 - cells, 237
 - ChIP-chip and ChIP-Seq, applications of, 757–758
 - CNG channel (*see* Cyclic nucleotide-gated (CNG) channels)
 - cyclic AMP, 824
 - cytoskeleton, 583–584
 - degeneration and survival, 584
 - GRK1 and GRK7 (*see* G protein-coupled receptor kinase (GRK))
 - HCN1 channel, mechanism of, 808
 - N*-ethylmaleimide sensitive factor (*see* *N*-ethylmaleimide sensitive factor (NSF))
 - OS protein transport, *tulp1*^{-/-} retina
 - animal model, 784–785
 - immunofluorescent staining, 785
 - localization, 785
 - trafficking, 786–787
 - survival, glucocorticoid-dependent mechanisms (*see* Glucocorticoid-dependent mechanisms)
 - Tulp1* complexes
 - crosslinked retinal samples, 705–706
 - homogenization, 704
 - in IS and OPL, 702
 - isolation and capture of, 704–705
 - laser microdissection, 703–704
 - retinal section preparation, 703
 - tcTPC, 703
 - Tulp1*^{-/-} mice, 702–703
 - Western blot analysis, 704, 705
 - zebrafish
 - morphogenesis, 434–435
 - significance, 433–434
 - vertebrate, 433

- Photoreceptor degeneration
Caenorhabditis elegans, 536–537
 HDAC inhibition (*see* HDAC inhibition, *Rdl* mouse)
- Photoreceptor mosaic imaging. *See* Adaptive optics (AO) imaging
- Photoreceptor neurons (PNs), 415
- Photoreceptor outer segment (POS), 693, 717, 731, 745
- Photoreceptor perisynaptic complex
 Cav1.4 α 1 subunit function, 740
 PMCA transporter and RIBEYE protein animal model, 740
 immunostaining, 740–741
 PMCA1 mislocalization, 741–742
- Phototransduction, 409–410
 cyclic nucleotide-gated channel, 769
 defects in, 832
 GPCR, 793
 GRK, 822
 protein interaction, 777
- P23H rhodopsin (RHO) photoreceptors
 BiP/Grp78 protein, 196–197
 control-injected eyes, 193
 ERG, 193
 gene therapy, 196
 genetic modifications, 191
 homozygous transgenic animals, 192
 HSF1 expression, 195–196
 human BiP/Grp78 expression, 193–194
 immunohistochemistry, 192
 mouse RHO 301 expression, 194
 retinal integrity, 194
 trafficking, 195
 transgenic rat, 196
- Pierce, E.A., 519
- Pigment epithelium-derived factor (PEDF), 69
- Pigment epithelium-derived factor receptor (PEDF-R)
 antibody, 800
 blocking peptides, 804–805
 immuno-blot, 801
 immunoreactivity
 rat retina R28 cell, as native, 803–804
 recombinant PEDF-R polypeptide, 802
 synthetic peptides, 802–803
 membrane fractionation, 801
 and PEDF interaction, 800
 peptides and proteins, 800
 phospholipase A activity, 800
 polyacrylamide gel electrophoresis, 801
 retina
 distribution, 799
pnpla2 gene, 799
 RPE and photoreceptor, 799
 slot blot, 801
- Pinealocytes, 514
- Pinter, R., 671
- Plasma membrane Ca²⁺ ATPases (PMCA), 740
- Platelet-derived growth factor receptor (PDGFR), 830
- PNPLA2. *See* Phospholipase A₂ (PNPLA2)
- Poliakov, E., 167
- Poly-ADP-ribosylated proteins (PAR), 110
- Polyvinylidene fluoride (PVDF), 770
- Pomares, E., 329
- Prentice, H., 269
- Programmed cell death (PCD). *See* Cell death
- Proinflammatory cytokines, 40
- Protein misfolding
 beta-sheet breakers, 569
 chaperone activation, 569–570
 gene therapy, 570
 loss-of-function, 568
 mediating factors cell toxicity, 570
 nonproductive intermediates, 567
 photoreceptor cells, 568–569
 RDS-peripherin, 568
 rhodopsin, 569
 therapeutic strategies, toxicity, 569
- Protein tyrosine-*O*-sulfation. *See* Sulfation
- Protein tyrosine phosphate-1B (PTP1B)
 insulin receptor signaling
 interaction between, 830–831
 in retina, 830
 nonreceptor PTP, 829
 retinal disease, activity in, 831
- RTK
 dephosphorylation and inactivation, 830
 JAK/STAT pathway, 830
 negative regulator, 829
 structure, 829
 therapeutic target, 831–832
- Provis, J., 31
- PTGS agents
 development, 146–147
 expression and animal testing, 151
 hammerhead ribozyme, 147
 lead candidate identification, 151
 lead candidate optimization, 150–151
 siRNA, 148
- Purpurin, 163–164
- Puthussery, T., 816

Q

- Qin, S., 745
 Qin, T., 43
 Qi, X., 83
 Quantitative reverse transcription-PCR (qRT-PCR)
 canine-specific TaqMan assay, 354–358
 experimental conditions, 361
 MDCK cell
 cell culture, 354, 359
 cellular viability assessment, 359
 Quantitative trait locus (QTL) analysis, 651

R

- RAC1, 582–584
 Radic, M.Z., 11
 RA domain-containing protein
 cell culture, 778
 domain assessment, 778
 Grb14, 781
 IR signaling, role in, 778
 PHLPP1 and PHLPP2
 assessment of, 779
 on CNG channel activity, effect of, 780–781
 sequence alignment, 778
 statistical methods, 778
 vectors, 778
 Rahman, A.K., 553
 Rajala, A., 777
 Rajala, R.V.S., 777, 829
 Ranchon-Cole, I., 140
 Rao, H.V., 83
 Rapamycin, 27, 280
 Rapp, M., 799
 Rayborn, M.E., 459
 RCS rats implantation
 photoreceptor survival, 119
 retinal function, 117–118
 Rd10 mice, retinal degeneration model
 autosomal recessive RP, 641
 cell shape, 643–642, 646
 dramatic changes in, 643, 644
 flatmount technique, 642
 mean data, 643, 644
 missense mutation, PDE6B, 641
 morphometrics, 643, 645
 Nikon C1 confocal imaging system, 643
 ZO-1 staining, 642
 Receptor tyrosine kinase (RTK), PTP1B
 dephosphorylation and inactivation, 830
 JAK/STAT pathway, 830
 negative regulator, 829
 Recombinant adeno-associated virus (rAAV)
 vector, 216, 218–219
 Redmond, M., 76
 Redmond, T.M., 167, 491
 Remé, C., 619
 Ren, Z., 43
 Retina
 ATP (*see* Adenosine 5'-triphosphate (ATP))
 cholesterol, 726
 function, 731
 HNC1 channels (*see* HCN1 channels)
 insulin receptor signaling in, 830
 photoreceptor outer segments, 693
 purine receptors, 814
 purinergic system, 813
 P2X7 receptor, role of
 microglial cells, 817
 Müller cell, 816–817
 neuronal degeneration, 815–816
 neuronal modulation, 815
 vs. P2X receptor, 815
 Retinal abnormalities, mice
 abnormal pathology, 468
 AFF, 464
 animal model, 460–461
 histology, 462
 imaging procedures, 462
 noninvasive ocular imaging, 467
 retinal arteriole-venous malformation, 463
 retinal morphology, 460
 RPE, 462–463
 SLO & OCT images, 464–467
 superior-temporal abnormality, 463
 visible fundus photography, 467
 Retinal atrophy and visual loss, 454–456
 Retinal cone-mediated signaling, 187–188
 Retinal degeneration, 138
 amyloid- β role (*see* Amyloid- β role)
 anticomplement strategy, 34
 apoptotic cells, 34
 ceramide signaling (*see* Ceramide signaling)
 Drosophila melanogaster
 ABCA4 gene, 408–409
 compound eye, 409–410
 genetic screening, 411
 phototransduction, 409–410
 red-eyed *Vs.* white-eyed, 408
 retinitis pigmentosa, 409

- Retinal degeneration (*cont.*)
- spontaneous mutation, 407
 - enzymatic cleavages, 31
 - gene association study, 32
 - in human, 411–412
 - hyperoxia, 33–34
 - MerTK phagocytic receptor, 693
 - pathogenic complement activation, 32
 - photoreceptor injury, 33
 - P23H-3 rodent, 33, 35
 - PTP1B activity, 831
 - Sprague Dawley (SD) rats, 32
 - zebrafish
 - drug discovery, 403
 - embryogenesis, 399
 - functional assessment, 401–402
 - genetic resources, 400–401
 - morphological and embryological features, 399–400
- Retinal degeneration slow (RDS)
- mutation in, 657
 - rod and cone outer segment biogenesis, 657
 - rods and cones
 - C150S-RDS expression, 636–637
 - disc rim formation, 636
 - OS morphogenesis, 636
 - and ROM-1 protein, 633, 636–638 (*see also* Rod outer segment membrane protein-1)
- Retinal degenerative disease (RDD)
- clinical examinations, 498
 - dark-adapted rod amplitude, 500–502
 - gene therapy, 152
 - human clinical translation, 151
 - lead candidate identification, 150
 - lead candidate optimization, 150–151
 - mRNA expression, 148
 - mRNA structure determinations, 148–149
 - pair-flash ERG results, 498
 - PTGS agents, 147–148
 - PTGS development, 146–147
 - PTGS expression and animal testing, 151
 - rod inactivation kinetics evaluation, 498–499
 - rod photoresponse recovery kinetics, 499–500
 - T_{sat} correlation, 500–502
- Retinal dystrophies, 519
- Bothnia-type (*see* Bothnia-type retinal dystrophy)
 - direct molecular diagnosis
 - mutation screening chips, 330, 331
 - next-generation sequencing, 332
 - resequencing chips, 330, 332
 - future aspects, 334
 - homozygosity mapping
 - autosomal recessive disease, 346
 - consanguineous vs. nonconsanguineous families, 347–349
 - future aspects, 350
 - population composition, 349
 - single nucleotide polymorphisms, 346
 - strengths and limitations, 350
 - indirect molecular diagnosis
 - cosegregation SNP-Chips, 333
 - homozygosity mapping, 332–333
 - optimized cost-effective multitiered strategy, 333–334
- Retinal ganglion cell (RGC), 161, 471
- growth and differentiation factor 11, 672
 - norrin-deficient mice, 681
 - transcription factors, 686
 - Brn-3* genes, 686–687
 - Dlx* genes, 687–688
 - islet genes, 689
 - Vax* genes, 688
- Retinal gene expression, 135
- Retinal injury
- in adult rats, 649
 - bioinformatic analyses, 651, 653–654
 - in *fld* mice, 655
 - network modulation, 651–653
 - online databases, 651, 653–654
 - patterns of, 650
- Retinal ischemia, 211
- Retinal light damage
- anemia, 138
 - aranesp/AMG114, 138, 139
 - Epo expression, 140, 141
 - Epo glycosylation analogs, 141
 - ERG amplitudes, 140, 141
 - intravitreal injections, 139
 - light-induced cell death, 138
 - nonhematopoietic cells, 141
 - ONL thickness, 140, 142
 - outer nuclear layer thickness, 140
 - retinal degenerations, 138
- Retinal neovascular disorders (RNV)
- age-related macular degeneration, 255
 - neovascularization
 - genetic mouse models, 255–256
 - nongenetic models, 256–257
 - preclinical drug testing, 257
 - proliferative diabetic retinopathy, 254
 - retinopathy of prematurity, 254
- Retinal nerve fibre layer (RNFL), 474
- Retinal pigment epithelial (RPE) cells, 452, 454, 462–463, 520–521, 535, 604–606
- antimycin A treatment, 27

- ARPE-19, 24–25
- bevacizumab, 28
- blood vessel growth, 27
- CD55 and CD59 inhibitors, 25, 26
- cell-cell contact, 641
- CNV, 24
- dendritic cell, 731, 735
- endo-lysosome network, 723–724
- FAK and MerTK, receptor activities, 719–720
- glycoprotein secretion, 731
- internalization, 720–721
- late endosome–lysosome (*see* Late endosome–lysosome)
- macrophages, 731, 735
- macula, 23
- melanosomes, 237
- morphometrics, 643, 645
- MYO7A* gene, 236
- oxidative stress, 24
- pattern and cell shape of, 642, 643
- phagocytosis
 - functional character of, 698
 - MerTK ligand study, 694
 - ORF phage, 694, 695
 - signaling, 693
 - Tulp1*^{-/-} mice, 694
- PR phagocytic machinery, molecules of
 - animal models, 718
 - “eat me” signal, 718
 - milk fat globule EGF-factor, 718–719
 - phosphatidylserine, 718
- ranibizumab, 28
- rapamycin, 27
- rd 10 mice
 - autosomal recessive RP, 641
 - flatmount technique, 642
 - mean data, 643, 644
 - missense mutation, PDE6B, 641
 - Nikon C1 confocal imaging system, 643
 - ZO-1 staining, 642
- RPE layer, 38
- shed POS, 709
- synchronized diurnal phagocytosis, rod POS, 735
- transglutaminase-2
 - animal and tissue collection, 710, 732
 - histology, 733
 - immunoblotting, 711
 - immunofluorescence microscopy, 711
 - localization and expression, 712–713
 - POS phagosome quantification, 733
 - TG2^{-/-} mice (*see* Transglutaminase-2 (TG2))
 - wild type vs. $\beta 5$ -/- eyecups, 711–712
 - vascular endothelial cell expression, 25
 - VEGF-R2 receptor, 26
 - zona occludens 1, tight junction molecule, 641
- Retinal pigment epithelial (RPE) cells
 - autophagy, 86–87
- Retinal pigment epithelium (RPE)
 - AMPK
 - allosterical activation, 746
 - cell barrier function, 747–748
 - cell inflammatory response, 748–749
 - cell survival, 749
 - cellular process, role in, 746
 - inactivation, 747
 - phagocytosis, 748
 - Ser/Thr kinase, 746
 - subunit, 746
 - via Thr¹⁷²Pphosphorylation, 746–747
 - cell signaling modification, 745–746
 - chronic oxidative stress, 745
 - drusen biogenesis and AMD pathogenesis, 745
 - functions, 745
 - location of, 745
- Retinal pigment epithelium (RPE) lipofuscin
 - A2E, 763
 - bisretinoid
 - A2-DHP-PE, 764–765
 - all-*trans*-retinal dimer vs. all-*trans*-retinal dimer PE, 763–764
 - biosynthetic pathways, 761–762
 - photooxidation, 765
- Retinal vascular permeability. *See* Betacellulin (BTC)
- Retinitis pigmentosa (RP), 107, 209, 409, 497, 584, 599, 781
 - adRP, 519
 - BCVA, 472
 - characteristics, 783
 - cohort study, 474
 - electrophysiological recordings, 472–473
 - ERAD, 562–563
 - ganglion cell functions, 476
 - heterogeneous inherited retinal disorder, 701
 - IMPDH1-linked
 - characterization, 539
 - enzymatic properties, 540
 - IMPDH and retina, 540
 - IMPDH structure and function, 540–541
 - retinal splice variants, 541–542
 - rhodopsin mutations, 539
 - translation regulation, 542–543

- Retinitis pigmentosa (RP) (*cont.*)
 inner retina structure-function relation, 475
 next-generation sequencing (NGS)
 bioinformatic analysis, 522–523
 RNA-seq analyses, 523
 pathophysiological processes, 477
 in photoreceptor, NSF role, 796
 photoreceptors death, 477
 pre mRNA processing factor mutation, 520
Prpf31-knockout animals, 520
 rd 10, autosomal recessive model, 641
 retinal disorder, 783
 retinal nerve fibre layer imaging, 474
 RGC morphology, 471
 RNA splicing factor mutant mice, 523
 RP diagnosis, 472
 RPE degeneration, 520, 521
 SMA, 520
SMN1 mutations, 521
- Retinitis pigmentosa GTPase regulator (RPGR)
 candidate modifier genes, 314, 315
 clinical diversity, 314
 data analysis, 315–316
 modifier SNPs, 316–317
 phenotypic heterogeneity, 316
 protein transport, 314
- Retinitis pigmentosa protein (RP2)
Chlamydomonas protein, 528
 cilia localisation and function, 528–529
 interaction partners, 529–530
 mutations, 527
 TBCC, 527–528
Trypanosome protein, 528
 UNC119, 529
 vesicle traffic, 528
- Retinol-binding protein (RBP4), 167
- Retinopathy of prematurity (ROP)
NDP mutations, 680
 neovascular ocular diseases, 246
 retinal neovascular disorders, 254
- Retinoschisis (RS1)
 clinical pathology, 515–516
 gene therapy, 516–517
 molecular pathology, 516
RS1 gene and protein, 514
 X-linked retinoschisis mutations, 515
- Reverse tetracycline transactivator (rtTA), 255
- Rex, T.S., 140
- Reynolds, A.L., 433
- Rha, J., 451
- RHO. *See* Rhodopsin (RHO)
- Rhodopsin (RHO), 103
 AAV gene delivery, 201–203
 animal models, 200
 electroretinography, 200–201
 pathologies, *Drosophila*
 abnormalities in phototransduction, 418
 maturation, trafficking and proteasomal clearance, 419–420
 mutations, 416–417
 PNs, 415
 programmed cell death, 420
Rh1 endocytosis and autophagy, 418–419
 PTP1B activity, 831
RHO301 gene cloning, 200
 translational vision research models program, 395–396
- Rho GTPases
 activation, 581–582
 overlapping function, 582
 photoreceptor
 cytoskeleton, 583–584
 degeneration and survival, 584
 retinal development, 582–583
- Ribbon synapses, 739
- Rinner, O., 823
- Ripamonti, C., 595
- Ritter, M.R., 251
- Rivera, A., 368
- RNV. *See* Retinal neovascular disorders (RNV)
- Robson, A.G., 595
- Rod inactivation kinetics evaluation, 498–499
- Rod ON-bipolar cells (RBCs), 130
- Rod opsin retinitis pigmentosa
 autophagy, 577–579
 characteristics, 573
 gene expression analysis, 574–575
 immunofluorescence, 574
 intracellular trafficking, 575
 P23H rhodopsin, 576, 577
 protein misfolding disease, 573
 TUNEL assay detection, 574
 UPR activation, 575
 vectors expression, 574
 western blotting, 574
 wild-type opsin, 577–578
- Rod outer segment membrane protein-1 (ROM-1)
 electron microscopy, 635
 electroretinography, 634–635
 gel electrophoresis and western blot analysis, 634
 ROM-1 overexpression, cone function and structure, 635–637
 ROM-1 protein expression, transgenic mice, 635, 636
 transgenic mice generation, 634

- Rohrer, B., 23, 34
 Rotstein, N.P., 557
 RPE. *See* Retinal pigment epithelium (RPE)
 Rpe65-deficiency
 AAV, 180
 Briard dogs, 177–178
 eye treatment, 180
 gene therapy
 phase I/II clinical trials, 179–180
 proof-of-principle trials, 179
 LCA, 177
 photoreceptor/cone degeneration, 178
 therapeutic intervention, 179
 treatment safety and efficacy, 180
RPGRIPI
 cilia assembly, 323–324
 cilia protein network, 322
 ciliogenesis, 324
 cytoskeleton dynamic regulation, 324
 expression, 322
 Ins44 mutation, 325–326
 knockout studies, 322
 molecular network components, 325
 retina, 322
 Ruggiero, L., 709, 731
 Rutar, M., 31
 Ryoo, H.D., 420
- S**
 Saadi, A., 553
 Saari, J.C., 590
 Salomon, R.G., 167
 Sancho-Pelluz, J., 107
 Santos, R., 671
 Sarang, Z., 731
 Sato, Y., 305
 Sauer, A., 337
 Scanning laser ophthalmoscopy (SLO),
 462–466, 479, 480
 Scaria, A., 573
 Schaich, S., 337
 Schey, K.L., 75
 Schmidt, J., 183
 Schwarz, N., 527
 Scotopic critical flicker frequency, 507–508
 SD-OCT. *See* Spectral domain optical
 coherence tomography
 SDS polyacrylamide gel (SDS-PAGE)
 R28 cell, membrane fractions, 804
 tissue lysate, Western blot of, 836
 Seeliger, M.W., 183, 491, 807
 Sezate, S.A., 245
 SFD. *See* Sorsby fundus dystrophy (SFD)
- Shang, F., 43
 Shared protein networks, maculopathy, 62–63
 Shi, L.Y., 391
 Sieving, P.A., 513
 Silvin, C., 381
 Singh, A., 769
 siRNA. *See* Small interfering ribonucleic acid
 (siRNA)
 Sliesoraityte, I., 471
 SLO. *See* Scanning laser ophthalmoscopy (SLO)
 Small interfering ribonucleic acid (siRNA)
 cell culture, 226–227
 CTRP5/*Ctrp5* expression, 230–231
 design, 226
 ELOVL4 mRNA
 ELOVL4-GFP fusion protein, 228
 protein expression, 227–228
 quantitative RT-PCR analysis, 229
 STGD3, 229
 wild-type ELOVL4 allele, 229
 rds expression
 AAV production, 217
 cell transfection, 216–217
 combination therapy, 220–222
 construction, 220
 electroretinogram, 217
 HEK-293 cells, 218
 rAAV-5 vector, 218–219
 RNA isolation, 217
 semiquantitative real-time PCR, 217
 statistical analysis, 218
 subretinal injection, 217
 transfection, 226–227
 transfection Cos-7 cells, 227
 Smith, A.J., 177
 Smith, G.W., 269
 Soluble interphotoreceptor matrix
 (S-IPM), 836
 Soluble interretinal pigment epithelium matrix
 (S-IRPEM), 836
 Song, A., 573
 Sonoda, H., 305
 Sorsby, A., 261
 Sorsby fundus dystrophy (SFD), 62
 angiogenesis molecular mechanism,
 264–265
 animal models, 264
 clinical manifestations, 262
 therapeutic intervention, 262
TIMP3
 AMD, 265
 molecular characteristics, 262
 mutation spectrum, 262
 Sparrow, J.R., 726, 761

- Spectral domain optical coherence tomography (SD-OCT)
 advantages, 491–492
 C57BL/6 wild-type mice, 494–495
 focal light damage, 493
 histological analysis, 492–493
 photoreceptor apoptosis, 495
 rapid degenerative process, 493
 retinal imaging, 492
 retinal structure, dynamic changes, 495
 rod outer segments, 493
- Spinal muscular atrophy (SMA), 520
- Sporadic maculopathy, 62
- Stabila, P., 93
- Stanton, C.M., 367
- Stargardt disease, 76, 167, 502
- Stargardt-like macular degeneration (STGD3),
 229, 232
- Stat3 protein, 430
- Staurosporin, 359, 360
- Stepien, K.E., 451
- Stocker, A., 589
- Stockman, A., 595
- Stöhr, H., 261
- Strauß, O., 603
- Strunnikova, N., 381
- Subramanian, P., 799
- Suburo, A.M., 101
- Sugimoto, M., 293
- Sugitani, K., 161, 445
- Sugrue, A., 83
- Sulfation
 bovine ocular tissues
 isolation of, 836
 PSG2 antibody, 838–839
 SDS-PAGE, 836–837
 S-IRPEM *vs.* IS-IRPEM, 838, 839
 Western blot analysis, 837–838
 human coagulation factor VIII, 836
 in multicellular eukaryotes, 835–836
 posttranslational modification, 835
 protein function, modification of, 835
 in retina and RPE, 836
 significance of, 836
- Sullivan, J.M., 145
- Sullivan, L.S., 313
- Suzuki, M., 155
- Szondy, Z., 731
- T**
- Tachibanaki, S., 823
- Taggart, R.T., 145
- Takahashi, K., 270
- Tam, L.C.S., 155, 547, 567
- Tamm, E.R., 679
- Tanimoto, N., 183, 807
- Tanito, M., 129
- Tao, W., 93
- Target of rapamycin (TOR) kinase, 208
- Thurman, J.M., 23
- Time-controlled transcardiac perfusion
 crosslinking (tcTPC), 702
- Timmers, A., 200, 217
- Toll-like receptor (TLR)-mediated cell
 response
 age-related macular degeneration (AMD)
 caspase-dependent apoptosis, 5
 CNV, 4
 L412F gene, 4, 6
 photoreceptor arrays, 5
 retinal pigment epithelium (RPE), 5–6
 VEGF-A polymorphism, 6
 neuroimmunity, 3–4
 short interfering RNA (siRNA)-based
 drugs, 6–7
- Tran, J.-T.A., 553
- Transcription factor (TF)
 ChIP-chip and ChIP-Seq analysis, 756
 chromatin-remodeling activity, 753
 distal enhancer, 753
 photoreceptor, role in, 757–758
 RGC cell, role in (*see* Retinal ganglion cell
 (RGC))
- Transferase dUTP nick end labeling
 (TUNEL), 109
- Transgenic mice
 β B1-crystallin norrin, 681
 ROM-1, cone photoreceptors, 634
- Transglutaminase-2 (TG2)
 animal and tissue collection, 710
 α v β 5 integrin-dependent phagocytosis,
 714
 β 1 or β 3 coreceptor, 710
 immunoblotting, 711
 immunofluorescence microscopy, 711
 TG2^{-/-} mice display
 morphology of, 733, 734
 rod POS phagocytosis, 733–735
 in vivo and immunoprecipitation
 studies, 732
 wild-type, localization
 mouse retina, 712–713
 rat RPE, primary culture, 713
 wild type *vs.* β 5^{-/-}-eyecups, 711–712
- Transient receptor potential (TRP), 409–410
- Translational vision research models program
 chemically induced mutants, 391

- clinical evaluation and electroretinography, 392
 - genetic mapping, 392
 - histological analysis, 393
 - mice origins and husbandry, 392
 - mutational analysis, 392
 - Pde6a* alleles, 393
 - rhodopsin mutation, 395–396
 - tubby-like protein 1, 393–395
 - Travis, G., 76, 726
 - Triton X100, 770
 - Troeger, E., 471
 - TRP. *See* Transient receptor potential (TRP)
 - Tsilfidis, C., 207
 - Tubby-like protein 1 (Tulp1), 393–395
 - C-terminal domain, 698
 - expression of, 783
 - location, 701
 - membrane vesicle preparation, 694, 695
 - mutation in, 701
 - neuronal function, 783
 - phagocytosis ligand, 696
 - photoreceptor compartment
 - crosslinked retinal samples, 705–706
 - homogenization, 704
 - in IS and OPL, 702
 - isolation and capture of, 704–705
 - laser microdissection, 703–704
 - retinal section preparation, 703
 - tcTPC, 703
 - Tulp1*^{-/-} mice, 702–703
 - Wester blot analysis, 704, 705
 - receptor, 696–697
 - role, 784
 - Tulp1^{-/-} mice, animal model
 - CO₂ inhalation, 784
 - immunofluorescent staining, 785
 - Tubulin cofactor C (TBCC), 527
 - Tyrosylprotein sulfotransferase (TPST), 835
- U**
- Ueffing, M., 61, 415
 - Unfolded protein response (UPR), 573
 - Usher syndrome type 1B
 - AAV-mediated gene therapy, 239
 - characterisation, 235
 - lentivirus-mediated gene therapy, 237–239
 - MYO7A* gene, 236
 - Myo7a*-mutant mice, 237, 238
 - strategies, 240
- V**
- Valter, K., 31, 121
 - Vascular endothelial growth factor (VEGF), 254, 279, 307
 - Vasireddy, V., 225
 - Vasohibin-1
 - corneal and retinal neovascularization, 309
 - expression, 307
 - mRNA extraction, 306–307
 - real-time polymerase chain reaction, 306–307
 - RPE
 - dynamics and proliferation, 307–309
 - preparation, 306
 - real-time RPE impedance analysis, 306
 - vascular maturation processes, 309
 - western blot analysis, 307
 - Vázquez-Chona, F.R., 349, 650, 652–654
 - Vessey, K.A., 813
 - Vijayasathy, C., 513
 - Vinores, S.A., 272
 - Visual system homeobox 2 (Vsx2)* gene
 - failed retinal development, 671
 - GDF11 levels (*see* Growth and differentiation factor 11 (GDF11))
 - micro-ophthalmia, 671
 - mutant mouse, 671–672
- W**
- Wadsworth, S., 573
 - Wagner-Schuman, M., 451
 - Wakusawa, R., 305
 - Walczak, Y., 619
 - Walker, T.A., 115
 - Wang, G., 369
 - Wang, J.J., 285, 391
 - Wang, T., 88
 - Wang, Z., 279
 - Wan, H., 11
 - Watson, R.F., 783
 - Webb, K.D., 313
 - Webb, T.R., 595
 - Weiss, E.R., 821
 - Wen, R., 93, 279
 - Wen, Y., 497
 - Western blot analysis
 - ROM-1 overexpression, 634
 - sulfation, bovine ocular tissues, 837–838
 - Tulp1, photoreceptor compartment, 704
 - Wheaton, D.K., 313
 - Wild type (WT), 148
 - Williams, D.S., 235
 - Williams, J.T., 313
 - Wissinger, B., 337

- Wittig, I., 770
 Wnt/ β -catenin signaling pathway
 DKK-1, inhibitor of, 681
 neurotropic growth factors, 681
 Wong, W.T., 37
 Won, J., 391
 Wright, A.F., 367
 Wright, G.A., 595
 Wu, D., 43
 Wu, J., 671
- X**
 Xia, X., 279
 Xing, W., 739
 X-linked cone dystrophy (XLCOD5). *See*
 OPN1LW and OPN1MW cone
 opsin gene
 X-linked inhibitor of apoptosis (XIAP)
 protein, 211–212
 X-linked juvenile retinoschisis (XLRS), 514
 X-linked progressive retinal atrophy 2
 (XLPRA2), 354
 X-linked retinitis pigmentosa, 314–315
- Y**
 Yamamoto, K., 761
 Yang, H., 553
 Yasumura, D., 215, 553
 Yau, E.H., 145
 Yetemian, R.M., 253
 Yu, M., 553
- Z**
 Zangerl, B., 321, 611
 Zebrafish
 light-damaged retina model, 427
 induction of Müller glial proliferation,
 429
 regeneration, 428–429
 mutation in genes encoding
 intracellular trafficking genes (*see*
 Intracellular trafficking genes)
 phototransduction protein, 435, 438
 screening, 435
 structural factor, 440
 structural protein, 440
 neuronal progenitor cell proliferation,
 429–430
 photoreceptor outer segment
 morphogenesis, 434–435
 significance, 433–434
 vertebrate photoreceptors, 433
 retina, HSP70 and HSF-1
 animal model, 664
 expression and localization, after ONI
 and heat shock, 665–667
 immunohistochemistry, 664
 mRNA mechanism, 665, 666
 in situ hybridization, 664–665
 tissue preparation, 664
 treatment, 664
 retinal degeneration
 drug discovery, 403
 embryogenesis, 399
 functional assessment, 401–402
 mitochondrial vertebrate, 400
 morphological and embryological
 features, 399–400
 mutant strain repository, 401
 screen, 400–401
 ZGC, 400
 retinal stem cell mutants, 441
 transcription factors for Müller
 glia, 430
 Zebrafish Gene Collection (ZGC), 400
 Zein, W.M., 381
 Zhang, C., 272
 Zhang, Q., 685
 Zhang, S.X., 285
 Zhao, C., 792
 Zhao, L., 37
 Zheng, L., 299
 Zhong, H., 773
 Zhong, Y., 285
 Zhu, M., 299
 Ziccardi, L., 513
 Zolotukhin, S., 217
 Zong, X., 183
 Zrenner, E., 471